ArticleEuropean journal of pediatrics2025
Urinary plasminogen as an early marker of diabetic kidney disease in children with type 1 diabetes mellitus: a cross-sectional study.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kidney organoids as a platform to study plasminogen-induced injury and uPA-based therapies.Stem cells translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aims to determine the role of urinary plasminogen, a serine protease that reflects damage to the glomerular filtration barrier, in the early detection of diabetic kidney disease in pediatric patients with type 1 diabetes mellitus (T1DM). Pediatric patients, who had been followed up with T1DM for at least 2 years, and healthy matched controls were included. The association between urine plasminogen (uPlasminogen) levels and urine plasminogen-to-creatinine ratio (uPlgCR) with urine albumin-to-creatinine ratio (uACR) was examined, as well as determining a cut-off value for uPlasminogen to predict microalbuminuria. A total of 56 T1DM patients and 30 healthy matched controls were included. There was no significant difference in eGFR (estimated glomerular filtration rate) and systolic and diastolic blood pressure between the groups. uPlasminogen level was determined to be higher in the albuminuric group than control (p = 0.001) and uPlgCR was higher in the normoalbuminuric and albuminuric groups than control (p = 0.004, p = 0.002, respectively). There was a weak positive correlation between uPlasminogen and uPlgCR with uACR (r 0.38, p = 0.004; r 0.28, p = 0.03, respectively). The diagnostic performance of uPlasminogen in predicting albuminuria was evaluated by ROC-curve analysis, showing an AUC of 0.69 (p = 0.02; 95% CI [0.521-0.861]), with a sensitivity of 75% and specificity of 65.5% at a cut-off value of 7.1 µg/L.
conclusionA positive correlation was found between uPlasminogen and uPlgCR with albuminuria. Also, uPlasminogen was determined to predict albuminuria. Most importantly, uPlgCR was elevated in diabetic patients before albuminuria developed. uPlgCR may serve as a potential early marker or therapeutic target of DKD, pending further longitudinal validation. WHAT IS KNOWN: • Urinary plasminogen correlates with albuminuria in diabetic patients. WHAT IS NEW: • Urinary plasminogen and uPlgCR levels exhibited a significant and positive correlation with uACR. The new findings in this study are that uPlgCR was detected in urine before microalbuminuria develops, and that uPlasminogen predicted albuminuria in pediatric patients with T1DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.